These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 30949709)

  • 41. In community-acquired bacterial pneumonia, lefamulin was noninferior to moxifloxacin at 96 h after the first dose.
    Powell D; Donato A
    Ann Intern Med; 2020 Feb; 172(4):JC22. PubMed ID: 32066155
    [No Abstract]   [Full Text] [Related]  

  • 42. Clinical Utility of Lefamulin: If Not Now, When?
    Mercuro NJ; Veve MP
    Curr Infect Dis Rep; 2020; 22(9):25. PubMed ID: 32834786
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program in 2010.
    Paukner S; Sader HS; Ivezic-Schoenfeld Z; Jones RN
    Antimicrob Agents Chemother; 2013 Sep; 57(9):4489-95. PubMed ID: 23836172
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Population pharmacokinetic analyses for BC-3781 using phase 2 data from patients with acute bacterial skin and skin structure infections.
    Rubino CM; Xue B; Bhavnani SM; Prince WT; Ivezic-Schoenfeld Z; Wicha WW; Ambrose PG
    Antimicrob Agents Chemother; 2015 Jan; 59(1):282-8. PubMed ID: 25348519
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Physiologically-based pharmacokinetic modeling of the drug-drug interaction between ivacaftor and lefamulin in cystic fibrosis patients.
    Amiel M; Ke A; Gelone SP; Jones HM; Wicha W
    CPT Pharmacometrics Syst Pharmacol; 2024 Apr; 13(4):589-598. PubMed ID: 38303579
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Simultaneous assessment of the pharmacokinetics of a pleuromutilin, lefamulin, in plasma, soft tissues and pulmonary epithelial lining fluid.
    Zeitlinger M; Schwameis R; Burian A; Burian B; Matzneller P; Müller M; Wicha WW; Strickmann DB; Prince W
    J Antimicrob Chemother; 2016 Apr; 71(4):1022-6. PubMed ID: 26747098
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetic/pharmacodynamic analysis to evaluate ceftaroline fosamil dosing regimens for the treatment of community-acquired bacterial pneumonia and complicated skin and skin-structure infections in patients with normal and impaired renal function.
    Canut A; Isla A; Rodríguez-Gascón A
    Int J Antimicrob Agents; 2015 Apr; 45(4):399-405. PubMed ID: 25700566
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Emerging antibiotics for community-acquired pneumonia.
    Liapikou A; Cilloniz C; Palomeque A; Torres T
    Expert Opin Emerg Drugs; 2019 Dec; 24(4):221-231. PubMed ID: 31657962
    [No Abstract]   [Full Text] [Related]  

  • 49. Health-Related Quality of Life as Measured by the 12-Item Short-Form Survey Among Adults With Community-Acquired Bacterial Pneumonia who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials.
    Lodise TP; Colman S; Alexander E; Stein DS; Fitts D; Goldberg L; Schranz J
    Open Forum Infect Dis; 2020 Jun; 7(6):ofaa209. PubMed ID: 32617376
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical Trial.
    Alexander E; Goldberg L; Das AF; Moran GJ; Sandrock C; Gasink LB; Spera P; Sweeney C; Paukner S; Wicha WW; Gelone SP; Schranz J
    JAMA; 2019 Nov; 322(17):1661-1671. PubMed ID: 31560372
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Low Prevalence of Gram-Positive Isolates Showing Elevated Lefamulin MIC Results during the SENTRY Surveillance Program for 2015-2016 and Characterization of Resistance Mechanisms.
    Mendes RE; Paukner S; Doyle TB; Gelone SP; Flamm RK; Sader HS
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670418
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A novel pleuromutilin antibacterial compound, its binding mode and selectivity mechanism.
    Eyal Z; Matzov D; Krupkin M; Paukner S; Riedl R; Rozenberg H; Zimmerman E; Bashan A; Yonath A
    Sci Rep; 2016 Dec; 6():39004. PubMed ID: 27958389
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacodynamic evaluation of lefamulin in the treatment of gonorrhea using a hollow fiber infection model simulating
    Jacobsson S; Golparian D; Oxelbark J; Wicha WW; da Costa RMA; Franceschi F; Brown D; Louie A; Gelone SP; Drusano G; Unemo M
    Front Pharmacol; 2022; 13():1035841. PubMed ID: 36452226
    [TBL] [Abstract][Full Text] [Related]  

  • 54. MIC Values of Iclaprim and Lefamulin against Mycobacterium abscessus Complex.
    Chew KL; Octavia S; Yeoh SF; Teo JWP
    Antimicrob Agents Chemother; 2021 Sep; 65(10):e0061921. PubMed ID: 34252305
    [No Abstract]   [Full Text] [Related]  

  • 55. Lefamulin in Patients with Community-Acquired Bacterial Pneumonia Caused by Atypical Respiratory Pathogens: Pooled Results from Two Phase 3 Trials.
    Paukner S; Mariano D; Das AF; Moran GJ; Sandrock C; Waites KB; File TM
    Antibiotics (Basel); 2021 Dec; 10(12):. PubMed ID: 34943700
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pleuromutilins: Potent Drugs for Resistant Bugs-Mode of Action and Resistance.
    Paukner S; Riedl R
    Cold Spring Harb Perspect Med; 2017 Jan; 7(1):. PubMed ID: 27742734
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia.
    Zhanel GG; Hartel E; Adam H; Zelenitsky S; Zhanel MA; Golden A; Schweizer F; Gorityala B; Lagacé-Wiens PR; Walkty AJ; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2016 Dec; 76(18):1737-1757. PubMed ID: 27909995
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antibacterial Activity and Pharmacokinetic Profile of a Promising Antibacterial Agent: 22-(2-Amino-phenylsulfanyl)-22-Deoxypleuromutilin.
    Zuo X; Fang X; Zhang Z; Jin Z; Xi G; Liu Y; Tang Y
    Molecules; 2020 Feb; 25(4):. PubMed ID: 32079232
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rational dosing of antimicrobial agents: pharmacokinetic and pharmacodynamic strategies.
    Owens RC; Shorr AF
    Am J Health Syst Pharm; 2009 Jun; 66(12 Suppl 4):S23-30. PubMed ID: 19502225
    [TBL] [Abstract][Full Text] [Related]  

  • 60. SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia.
    File TM; Rewerska B; Vucinic-Mihailovic V; Gonong JRV; Das AF; Keedy K; Taylor D; Sheets A; Fernandes P; Oldach D; Jamieson BD
    Clin Infect Dis; 2016 Oct; 63(8):1007-1016. PubMed ID: 27448679
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.